Nothing Special   »   [go: up one dir, main page]

NZ600243A - Combination of theobromine with a decongestant and its use for the treatment of cough - Google Patents

Combination of theobromine with a decongestant and its use for the treatment of cough

Info

Publication number
NZ600243A
NZ600243A NZ600243A NZ60024310A NZ600243A NZ 600243 A NZ600243 A NZ 600243A NZ 600243 A NZ600243 A NZ 600243A NZ 60024310 A NZ60024310 A NZ 60024310A NZ 600243 A NZ600243 A NZ 600243A
Authority
NZ
New Zealand
Prior art keywords
decongestant
theobromine
cough
treatment
combination
Prior art date
Application number
NZ600243A
Inventor
John Brew
Robin Mark Bannister
Original Assignee
Biocopea Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocopea Ltd filed Critical Biocopea Ltd
Publication of NZ600243A publication Critical patent/NZ600243A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ABSTRACT - 600243 The disclosure relates to an agent consisting of theobromine and a decongestant as a combined preparation for use in a therapy of cough, wherein the agent is manufactured for administration by an oral route, wherein the decongestant is selected from ephedrine, levmetamfetamine, naphazoline, oxymetazoline, phenylephrine, phenylpropanolamine, propylhexedrine, pseudoephedrine, synephrine and tetrahydrozoline, and wherein the decongestant, preferably pseudoephedrine, is to be administered in a dose of 0.1 to 30 mg/kg/day.
NZ600243A 2009-12-14 2010-12-14 Combination of theobromine with a decongestant and its use for the treatment of cough NZ600243A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0921805.8A GB0921805D0 (en) 2009-12-14 2009-12-14 Drug composition and its use in therapy
PCT/GB2010/052085 WO2011073646A1 (en) 2009-12-14 2010-12-14 Combination of theobromine with a decongestant and its use for the treatment of cough

Publications (1)

Publication Number Publication Date
NZ600243A true NZ600243A (en) 2013-07-26

Family

ID=41667045

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ600243A NZ600243A (en) 2009-12-14 2010-12-14 Combination of theobromine with a decongestant and its use for the treatment of cough

Country Status (18)

Country Link
EP (1) EP2512464A1 (en)
JP (2) JP2013513651A (en)
CN (2) CN105816462A (en)
AU (1) AU2010332494B2 (en)
BR (1) BR112012014161A2 (en)
CA (1) CA2784214C (en)
CO (1) CO6541630A2 (en)
EC (1) ECSP12012132A (en)
GB (1) GB0921805D0 (en)
IL (1) IL220383A (en)
MX (1) MX343222B (en)
NZ (1) NZ600243A (en)
PE (1) PE20121537A1 (en)
RU (1) RU2564904C2 (en)
SG (2) SG10201408377QA (en)
UA (1) UA105944C2 (en)
WO (1) WO2011073646A1 (en)
ZA (1) ZA201204293B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9308211B2 (en) 2009-06-16 2016-04-12 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
US10016437B2 (en) 2009-06-16 2018-07-10 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
GB201111485D0 (en) * 2011-07-05 2011-08-17 Biocopea Ltd Drug composition and its use in therapy
GB0910375D0 (en) 2009-06-16 2009-07-29 Biocopea Ltd Drug composition and its use in therapy
US9314465B2 (en) 2009-06-16 2016-04-19 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7604094A (en) * 1993-09-07 1995-03-27 Procter & Gamble Company, The Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive
HUP9700654A2 (en) * 1997-03-26 1999-09-28 Dezső Korbonits Antitussive compositions containing theobromine
US6417206B1 (en) * 2001-01-26 2002-07-09 Medpointe Healthcare Inc. Antitussive/antihist aminic/decongestant compositions
JP2002308761A (en) * 2001-04-09 2002-10-23 Taisho Pharmaceut Co Ltd Antitussive agent for common cold
JP2003128549A (en) * 2001-08-15 2003-05-08 Rohto Pharmaceut Co Ltd Composition applicable to mucous membrane
JP4377564B2 (en) * 2002-05-02 2009-12-02 ロート製薬株式会社 Composition for internal use
RU2311919C2 (en) * 2002-12-30 2007-12-10 Каунсел Оф Сайнтифик Энд Индастриал Рисерч Development of anti-coughing and throat softening herbal composition
US20040202677A1 (en) * 2003-04-10 2004-10-14 Hopkins Kevin J. Method of enhanced regional body fat reduction
US20060153926A1 (en) * 2005-01-10 2006-07-13 Bascom Charles C Compositions, products and methods for controlling weight in a mammal
US20080003280A1 (en) * 2006-06-26 2008-01-03 Levine Brian M Combination cough treatment compounds and method of treating common coughs
KR20080009994A (en) * 2006-07-25 2008-01-30 안국약품 주식회사 Compositions for treating of cough
CN100518775C (en) * 2007-03-16 2009-07-29 邓丽菊 Medicine composition for treating cough and asthma and preparation thereof

Also Published As

Publication number Publication date
JP2013513651A (en) 2013-04-22
ECSP12012132A (en) 2012-09-28
SG10201408377QA (en) 2015-02-27
GB0921805D0 (en) 2010-01-27
WO2011073646A1 (en) 2011-06-23
EP2512464A1 (en) 2012-10-24
PE20121537A1 (en) 2012-12-21
BR112012014161A2 (en) 2016-05-17
CA2784214C (en) 2018-01-09
JP2016040279A (en) 2016-03-24
SG181686A1 (en) 2012-07-30
CA2784214A1 (en) 2011-06-23
UA105944C2 (en) 2014-07-10
MX2012006625A (en) 2012-10-05
MX343222B (en) 2016-10-28
CO6541630A2 (en) 2012-10-16
RU2012129839A (en) 2014-01-27
IL220383A (en) 2017-01-31
RU2564904C2 (en) 2015-10-10
AU2010332494B2 (en) 2015-01-15
CN102740843A (en) 2012-10-17
CN105816462A (en) 2016-08-03
IL220383A0 (en) 2012-08-30
ZA201204293B (en) 2013-02-27
AU2010332494A1 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
WO2009152189A8 (en) Low dose topiramate/phentermine compostion and methods of use thereof
AR124500A2 (en) INCREASED BIOAVAILABILITY OF THE DRUG IN NALTREXONE THERAPY
NZ605888A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
NZ713202A (en) Diagnosis and treatments relating to th2 inhibition
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
MX2010005631A (en) Novel cyclic hydrocarbon compounds for the treatment of diseases.
NZ589445A (en) Rasagiline for parkinson's disease modification
RS51688B (en) Concentrated methotrexate solutions
AR065392A1 (en) METHODS FOR TREATMENT BY INHALATION OF A DISEASE OR RESPIRATORY STATE
WO2012007159A3 (en) Novel gastro-retentive dosage forms
AR124497A2 (en) METHODS TO TREAT BINGE EATING OR COMPULSIVE EATING; USE OF BUPROPRION AND NALTREXONE TO PREPARE A MEDICATION FOR SUCH METHODS, AND PHARMACEUTICAL COMPOSITION
ITBO20110012A1 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING RIFAXIMINA AND THEIR USE.
BR112012016783A2 (en) "Uses of the naltrexone compound or pharmaceutically acceptable salt thereof to bupropion or pharmaceutically acceptable salt thereof or composition thereof and methods for providing therapy"
NZ600243A (en) Combination of theobromine with a decongestant and its use for the treatment of cough
NZ594067A (en) VISFATIN THERAPEUTIC AGENTS (PEPTIDES, siRNA, FK-866, APO866 ) FOR THE TREATMENT OF ACNE AND OTHER CONDITIONS
WO2011047837A3 (en) Melt-granulated cinacalcet
AR079000A1 (en) ANTI-BANK THERAPY AIMED AT CANCEROSA MOTHER RESISTANT DRUG CELLS
MX341660B (en) Ghrelin receptor agonist for treatment of dyscrasia.
WO2009019693A3 (en) Analgesic effect of jasmonate derivatives
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol
MX2008015323A (en) Pharmaceutical composition comprising cyclobenzaprine and aceclofenac in association.
MD3422G2 (en) Method of prophylaxis and treatment of gallinaceae knemidokoptosis
GR1008614B (en) 3,3-diphenyl-n-(phenylethyl) propan-1-amine used as a new selective ligand of the sigma-1 receptors, having anti-apoptotic (cytoprotective) properties and prototypical anticancer activity
GB201100804D0 (en) Drug combination
RU2008107113A (en) MEANS AND METHOD FOR PREVENTION AND TREATMENT OF PATIENTS WITH ALZHEIMER'S DISEASE

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 DEC 2015 BY OLCOTT

Effective date: 20141012

ASS Change of ownership

Owner name: INFIRST HEALTHCARE LIMITED, GB

Effective date: 20141106

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 DEC 2016 BY OLCOTT

Effective date: 20151128

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 DEC 2017 BY OLCOTT INTERANTIONAL

Effective date: 20161205

LAPS Patent lapsed